Enlargement of the European Union (EU) offers historic opportunities, both to applicants and to existing member states. Securing these opportunities will be important to enhance and strengthen the EU relative to its international competitors. The competitiveness of the high technology industries, such as the pharmaceutical industry, is a genuine asset to Europe, but it also creates some problems.
From the pharma industry’s perspective, the question of whether the expansion of the EU is regarded as a threat or an opportunity clearly depends on a company’s own strategies, positioning in the marketplace and product portfolio. The areas likely to be most affected by the impact of accession are cross-border trade, the growth of the genetics market and raising questions of whether ‘parallel imports’ may increase as a result of the expansion.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]